Revance Therapeutics | RVNC - 应收帐款人



应收帐款人 更改 日
AbbVie USD 12.59B 180M 2025-12
ALKERMES USD 456.48M 48.85M 2026-06
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Cara Therapeutics USD 2.24M 2.26M 2025-03
Coherus Biosciences USD 18.42M 232.08M 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
J&J USD 22.54B 1.21B 2026-03
Merck USD 11.78B 345M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
P&G USD 6.28B 208M 2025-12
Pacira USD 125.64M 1.57M 2026-03
Supernus Pharmaceuticals USD 182.18M 5.62M 2026-03